Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus

Clinical and Experimental Immunology

Volumn 118, Issue 1, 1999, Pages 30-34

  Gargiulo, Patrizia ^b   Goldberg, J ^a   Romani, B ^b   Schiaffini, R ^b   Ciampalini, P ^b   Faulk, W P ^a   McIntyre, J A ^a  

^a METHODIST HOSPITAL   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti phospholipid antibodies; Diabetic complications; Diabetic retinopathy; Endothelial dysfunction; Haemostasis; Phosphatidylethanolamine

Indexed keywords

AUTOANTIBODY; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; QUALITATIVE DIAGNOSIS; QUANTITATIVE ASSAY; RECEPTOR DOWN REGULATION; TARGET CELL;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; CARDIOLIPINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHOSPHATIDYLETHANOLAMINES; PHOSPHATIDYLSERINES; PROTEIN C; SENSITIVITY AND SPECIFICITY;

EID: 2142825496     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01014.x     Document Type: Article

References (55)

1. 1 Barnett AH. Pathogenesis of diabetic microangiopathy: an overview. Am J Med 1991; 90 (Suppl. 6A):67S-73S1.
2. 2 Andreani D. The labyrinth of diabetic vascular disease: crossroads and ways out. Diab Nutr Metab 1995; 8:54-64.
3. 3 Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36:1119-25.
4. 4 Stehouer CDA, Zellenrath P, Polak BCP et al. Von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type I (insulin-dependent) diabetes mellitus and normal urinary albumin secretion. Diabetologia 1992; 35:555-9.
5. 5 Walmsley D, Hampton KK, Grant PF. Contrasting fibrinolytic responses in type I (insulin-dependent) and type 2 (non insulin-dependent) diabetes. Diab Med 1991; 8:954-9.
6. 6 Gargiulo P, Schiaffini R, Bosco D et al. Diabetic microangiopathy: lupus anticoagulant dependent thrombotic tendency in type I diabetes mellitus. Diab Med 1997; 14:132-7.
7. 7 Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus: call for data. Diabetes 1991; 40:653-9.
8. 8 Jones DB, Wallace R, Frier BM. Vascular endothelial cell antibodies in diabetic patients. Association with diabetic retinopathy. Diabetes Care 1992; 15:552-5.
9. 9 Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998; 101:2029-35.
10. 10 Hughes GRV. Antiphospholipid syndrome: ten years on. Lancet 1993; 343:341-4.
11. 11 McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection. An overview. Am J Reprod Immunol 1997; 37:101-10.
12. 12 Derksen RHWM, de Groot G, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52:689-92.
13. 13 Vogel JJ, Reber G, de Moerloose P. Laboratory and clinical features in systemic lupus erythematosus patients with or without anticardiolipin antibodies. Thromb Res 1991; 62:545-56.
14. 14 Lopez LR, Santos ME, Espinoza LR, La Rosa FG. Clinical significance of immunoglobulin A versus immunoglobulin G and M anticardiolipin antibodies in patients with lupus erythematosus: correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol 1993; 98:449-54.
15. 15 Foley-Nolan D. Anticardiolipin antibody titers in patients with myocardial infarction. Am J Cardiol 1991; 68:830-1.
16. 16 Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gribelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998; 29:1759-64.
17. 17 McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies in heart transplant recipients. Clin Cardiol 1995; 18:575-80.
18. 18 Wagenknecht DR, Carter CB, McIntyre JA. Antiphospholipid antibodies are implicated in early renal allograft failure. Clin Hemostas Rev 1998; 12:19.
19. 19 Ducloux D, Pellet E, Fournier V, Rebibou JM, Bresson-Vautrin C, Racadat E, Fellmann D, Chalopin JM. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67:90-93.
20. 20 Jurcevic S, Dunn MJ, Crisp S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65:1197-202.
21. 21 Lorini R, d'Annunzio G, Montecucco C. Anticardiolipin antibodies in children and adolescents with insulin dependent diabetes mellitus. Eur J Pediatr 1995; 154:105-8.
22. 22 Vinik AI, Leichter SB, Pittenger GL, Stansberry KB, Holland MT, Powers AC, Suwanwalaikorn S. Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Diabetes Care 1995; 18:1225-32.
23. 23 Shigeta H, Fujii M, Yamaguchi M et al. Serum autoantibodies agonist sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 1997; 20:1896-9.
24. 24 Lecerf V, Athenc-Gelas M, Laurian C et al. Antiphospholipid antibodies in atherosclerosis. Am J Med 1992; 92:575-6.
25. 25 Diabetic Retinopathy Study Research Groups. Report 7: a modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Visual Sci 1981; 21:210-26.
26. 26 Wagenknecht DR, Sugi T, McIntyre JA. The evolution, evaluation and interpretation of antiphospholipid antibody assays. Clin Immunol Newsletter 1995; 15:28-38.
27. 27 Wagenknecht DR, McIntyre JA. Changes in β2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69:361-5.
28. 28 Bevers FM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66:629-32.
29. 29 Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen PE complex. Blood 1995; 86:3083-9.
30. 30 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76:354-60.
31. 31 Kutteh WH, Wester R, Kuttch CC. Multiples of the median: an alternative method for reporting antiphospholipid antibodies in women with recurrent pregnancy loss. Obstet Gynecol 1994; 84:811-5.
32. 32 Wroblewski M, Fernlund P, Gottzater A, Sundkvist G, Lindgarde F. Gender, autoantibodies and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 1998; 21:250-5.
33. 33 Schranz D, Lernmark A. Immunology in diabetes: an update. Diab/Met Rev 1998; 14:3-29.
34. 34 Elbein SC, Hoffman MD, Mayorga RA, Barrett KL, Leppert M, Hasstedt S. Do non-insulin-dependent diabetes mellitus (NIDDM) and insulin-dependent diabetes mellitus (IDDM) share genetic susceptibility loci? An analysis of putative IDDM susceptibility regions in familial NIDDM. Metabolism 1997; 46:48-52.
35. 35 Drouvalakis KA, Buchanan RC. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants: association of phosphatidylethanolamine reactivity with thrombosis in autoimmune diseases. J Rheumatol 1998; 25:290-5.
36. 36 Acerinic CL, Ahmed ML, Ross KM, Sullivan PB, Bird G, Dunger DB. Cocliac disease in children and adults with IDDM. Clinical characteristics and response to gluten-free diet. Diab Med 1998; 15:38-44.
37. 37 Sammaritano LR, Lockshin MD, Gharavi AE. Antiphospholipid antibodies differ in aPL cofactor requirements. Lupus 1992; 1:83-90.
38. 38 Matsuuru E, Igarashi Y, Fujimoto M et al. Heterogeneity of anticardiolipin antibodies defined by anticardiolipin cofactor. J Immunol 1992; 248:3885-91.
39. 39 Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336:177-8.
40. 40 Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996; 5:388-92.
41. 41 Tanne D, Triplett DA, Levine SR. Antiphospholipid antibodies and ischemic stroke. Not just cardiolipin anymore. Stroke 1998; 29:1755-8.
42. 42 Triplett DA. Antiphospholipid protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Haemostasis 1996; 26 (Suppl. 4):358 -67.
43. 43 Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24:1083-8.
44. 44 Boddi M, Prisco D, Fedi S, Cellai AP, Liotta AA, Parett E. Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thromb Res 1996; 82:207-16.
45. 45 Fields RA, Toubbeh H, Seoules RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16:623-5.
46. 2-Glycoprotein 1-dependent and independent anticardiolipin antibody in non-obese diabetic (NOD) mice. Clin Exp Immunol 1998; 111:173-80.
47. 47 Markey AC, MacDonald DM. Systemic lupus erythematosus with complement deficiency and IgA anti-cardiolipin antibody. Br J Dermatol 1998; 119:633-7.
48. 48 Schena FP, Pastore A, Sinico RA, Montinaro B, Fomasieri A. Polymeric IgA and IgA rheumatoid factor decrease the capacity of serum to solubilize circulating immune complexes in the patients with primary IgA nephropathy. J Immunol 1988; 141:125-30.
49. 49 Faulk WP, Labarrere CA. Fibrinolytic and anticoagulant control of hemostasis in human cardiac and renal allografts. In: Hammond EH, ed. Major problems in pathology. Philadelphia: W.B. Saunders, 1994:49-65.
50. 50 Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Eng J Med 1995; 333:1111-6.
51. 51 King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Ann Rev Med 1994; 45:179-88.
52. 52 Rodriquez-Segade S, Camina MF, Paz, JM, Del Rio R. Abnormal serum immunoglobulin concentrations in patients with diabetes mellitus. Clin Chim Acta 1991; 203:135-42.
53. 2 antibodies in patients with type 2 (non insulin dependent) diabetes mellitus and microangiopathy. Diabetes Res 1990; 15:195-200.
54. 54 Rowley AH, Eckerly CA, Hans-Martin J, Shulman ST, Bakar SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997; 159:5946-55.
55. 55 Ejskjaer NT, Zanone MM, Peakman M. Autoimmunity in diabetic autonomic neuropathy: does the immune system get on your nerves? Diabetes Med 1998; 15:723-9.